Orapi Past Earnings Performance

Past criteria checks 0/6

Orapi's earnings have been declining at an average annual rate of -76.2%, while the Chemicals industry saw earnings growing at 3.7% annually. Revenues have been declining at an average rate of 2.7% per year.

Key information

-76.2%

Earnings growth rate

-72.9%

EPS growth rate

Chemicals Industry Growth4.3%
Revenue growth rate-2.7%
Return on equity-90.5%
Net Margin-11.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Orapi makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0ICI Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24226-27900
31 Mar 24228-23880
31 Dec 23229-19870
30 Jun 23228-7870
31 Mar 23227-3880
31 Dec 222271890
30 Jun 222280930
31 Mar 222270930
31 Dec 212270930
30 Sep 212362970
30 Jun 2124531010
31 Mar 2125661030
31 Dec 2026891050
30 Sep 2026051010
30 Jun 202520970
31 Mar 20246-1970
31 Dec 19240-3970
30 Sep 1924701010
30 Jun 1925431050
31 Mar 1925501080
31 Dec 18256-41100
30 Sep 18251-41100
30 Jun 18247-41090
31 Mar 18245-31090
31 Dec 17244-21090
30 Sep 17243-11090
30 Jun 1724201090
31 Mar 17245-11110
31 Dec 16248-11130
30 Sep 16255-31160
30 Jun 16263-41190
31 Mar 16270-51220
31 Dec 15277-61260
30 Sep 15265-31210
30 Jun 15252-11160
31 Mar 1523601100
31 Dec 1422021050
30 Sep 1422021050
30 Jun 1422121050
31 Mar 1421631030
31 Dec 1321131010

Quality Earnings: 0ICI is currently unprofitable.

Growing Profit Margin: 0ICI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0ICI is unprofitable, and losses have increased over the past 5 years at a rate of 76.2% per year.

Accelerating Growth: Unable to compare 0ICI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0ICI is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-13%).


Return on Equity

High ROE: 0ICI has a negative Return on Equity (-90.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:45
End of Day Share Price 2024/11/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orapi SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephanie LefebvreGilbert Dupont